Diffuse Intrinsic Pontine Glioma (DIPG) is a rare, aggressive, and fast-growing pediatric brain tumor. It originates in the pons—a critical structure within the brainstem that acts as the central command post for essential bodily functions, including breathing, heart rate, blood pressure, balance, speech, and swallowing.

Because DIPG grows "diffusely" (interweaving directly into healthy brain stem tissue rather than forming a distinct mass), surgical removal is impossible. Doing so would damage the delicate neural pathways required for life.

In recent years, medical science has updated its terminology. DIPG is now classified under the broader umbrella of Diffuse Midline Glioma (DMG), specifically characterized in most cases by a genetic alteration known as the H3 K27M mutation. While "DMG" is the updated medical term, "DIPG" remains widely used when referring specifically to tumors originating in the pons.

• Pediatric Impact: Approximately 200 to 300 children in the United States are diagnosed with DIPG each year. It accounts for roughly 10% to 15% of all pediatric brain tumors.

• Peak Age: While DIPG can occur at any age, it is most commonly diagnosed in children between 5 and 9 years old.

• Prognosis: DIPG remains the leading cause of death from pediatric brain cancer. The median survival time following diagnosis is approximately 9 to 11 months, with fewer than 10% of children surviving past two years and a 5-year survival rate of less than 2%.

• Unchanged Statistics: Despite decades of research and medical advancements in other pediatric cancers, the overall survival rate for DIPG has remained largely unchanged for over forty years, underscoring the urgent need for targeted funding and innovative therapies.

DIPG is not caused by environmental factors, lifestyle, or genetics passed down through families; it is a heartbreakingly random genetic mishap. Because pediatric brain cancer research receives only a tiny fraction of general cancer funding, grassroots organizations, family-led foundations, and independent clinical trials are vital to advancing science. Continued research, expanded tissue donation, and clinical trial participation are key to unlocking effective treatments and, ultimately, finding a cure.